Keymed Biosciences (HKG:2162) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems

Simply Wall St21:18 ET

HK stocks surge: Afternoon surge of nearly 5% in Cansino Biologics (02162); Simcere seeks injection of anti-PD-1 monoclonal antibody drug listing approval, application accepted by the National Medical Products Administration.

Kanoya-B (02162) rose nearly 5% in the afternoon. At the time of publication, it rose 4.46%, to HKD 35.15, with a turnover of HKD 16,130.3 million.

Zhitong FinanceJun 13 01:59 ET

Keymed Biosciences' Rhinosinusitis Drug Gets NDA Application Acceptance From NMPA

Keymed Biosciences (HKG:2162) said its new drug application, Stapokibart injection, for the treatment of chronic rhinosinusitis with nasal polyps, has recently been accepted by China's National Medic

MT NewswiresJun 7 02:32 ET

The pharmaceutical, suphikubaidankang injection, used for treating chronic sinusitis and nasal polyps, has obtained market approval application acceptance from the National Medical Products Administration for Conoia-B (02162.HK).

On June 7th, Gelunhui announced that the application for market approval of Simcyprian Monoclonal Antibody Injection, which treats chronic sinusitis with nasal polyps, has been accepted by the National Medical Products Administration ('NMPA') and is included in the priority review and approval process. This application is based on a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study, which is mainly used to confirm the efficacy and safety of Simcyprian Monoclonal Antibody Injection in the treatment of chronic sinusitis with nasal polyps. The results of the study showed that the data from this Phase III clinical trial was positive, and the joint primary endpoints were achieved.

Gelonghui FinanceJun 6 20:02 ET

Express News | KeyMed Biosciences -New Drug Application of Stapokibart Injection for- Treatment of Chronic Rhinosinusitis With Nasal Polyps- Accepted by Nmpa

ReutersJun 6 20:01 ET

[Brokerage Focus] Bocom Intl expects current high cost performance in medical sector, but industry sentiment has not fully recovered.

Jingu Finance Xintong | Bank of Communications International released the outlook for the pharmaceutical industry in the second half of 2024. They think that the pharmaceutical sector currently has high cost-effectiveness, but institutional positions have fallen to a low level and industry sentiment has not fully recovered. The bank recommends laying out three main themes in 2H24: 1) The Davis double-click opportunity of valuation bottoming out and performance rebounding; 2) Innovation is the theme of the industry's long-term development, taking into account the potential for product export; 3) Defensive opportunities with stable performance and high shareholder returns. The bank's preference ranking for segmented sectors is as follows: prescription drugs = innovative drugs > high dividend traditional Chinese medicine/circulation > private hospitals > CXO. Specifically, prescription drugs - performance growth rebound + valuation.

金吾財訊Jun 5 20:35 ET